The global market for HAI products is estimated at between $10 billion and $15 billion in 2010, depending on the products included in the study, with high single-digit growth through 2016. Although the U.S. holds between 45% and 50% of the market, the fastest-growing regions for HAI treatments are the Asia-Pacific, which includes China, and Brazil.
STUDY GOALS AND OBJECTIVES
Healthcare-acquired infections are viral, bacterial, or fungal infections that patients acquire after they are admitted to a healthcare facility. Patients can acquire these infections from routine care; surgery; or as a complication from the use of medical devices such as ventilators, catheters, and intravenous lines.
The Centers for Disease Control (CDC) estimates that 2 million HAIs occur annually in the U.S. This leads to 100,000 deaths and costs an additional $36 billion to $45 billion in direct medical costs annually.
This report is designed to investigate the global HAI market by treatment area and by treatment type, with supporting tables and figures to illustrate projected growth. The report will include the U.S., Europe, Japan, and other countries such as China.
This report offers forecasts of the markets for devices, pharmaceuticals, and therapies by treatment segment and treatment type from 2011 through 2016, including supporting analyses for projections.
This report is a valuable tool for anyone assessing the HAI market and attempting to devise a strategy to successfully compete in this market. It provides background on the structure of the HAI market and the chief challenges and opportunities it faces. It offers the information needed to understand the current market and to address the emerging one.
This is an invaluable tool for business planners; acquisition specia
Copyright©2010 PR Newswire.
All rights reserved